ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
Dow Jones
39.127,80
0,04%
Euro vs US Dollar
1,06917
0,11%
Bitcoin
60.988,55
0,29%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Eli Lilly and Co (LLY)

  7. Eli Lilly and Co (LLY) News

LLY

Eli Lilly (LLY)

Eli Lilly and Co
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:LLY
DatumZeitQuelleÜberschriftSymbolFirma
25/06/202416h00PR Newswire (US)Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteriaNYSE:LLYEli Lilly and Co
24/06/202417h30PR Newswire (US)Lilly Declares Third-Quarter 2024 DividendNYSE:LLYEli Lilly and Co
24/06/202413h00IH Market NewsUPS Divests Coyote Logistics in $1.025 Billion Deal with RXO, Under Armour Agrees to $434 million Settlement, and More NewsNYSE:LLYEli Lilly and Co
21/06/202421h49PR Newswire (US)Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolutionNYSE:LLYEli Lilly and Co
18/06/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
18/06/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
18/06/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
18/06/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
18/06/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
18/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
17/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
14/06/202420h49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
11/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
11/06/202413h11IH Market NewsFDA Panel Supports Eli Lilly’s Donanemab, Rio Tinto Expands Stake in Boyne Smelters, and More NewsNYSE:LLYEli Lilly and Co
10/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
08/06/202415h03PR Newswire (US)Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeksNYSE:LLYEli Lilly and Co
07/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
07/06/202420h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
06/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
05/06/202420h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
05/06/202413h48Edgar (US Regulatory)Form 8-K - Current reportNYSE:LLYEli Lilly and Co
05/06/202413h45PR Newswire (US)Lilly announces departure of Anat Ashkenazi, chief financial officerNYSE:LLYEli Lilly and Co
04/06/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
04/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
04/06/202415h00PR Newswire (US)Melissa Seymour to join Lilly as executive vice president of Global QualityNYSE:LLYEli Lilly and Co
04/06/202400h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
04/06/202400h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:LLYEli Lilly and Co
03/06/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
03/06/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
03/06/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LLYEli Lilly and Co
 Showing the most relevant articles for your search:NYSE:LLY

Kürzlich von Ihnen besucht

COIN
ETHUSD
Ethereum
FX
EURGBP
Euro vs Sterling
USOTC
ADDYY
Adidas (QX)
TG
ALV
Allianz
TG
NOV
Novo Nordisk
TG
MBG
MercedesBenz
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
NYSE
KO
Coca Cola
NYSE
MRK
Merck
DBI
DAX
DAX
TG
TUI1
Tui
TG
D7G
Nel ASA
NYSE
JPM
JP Morgan Chase
CCOM
US30
US 30
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten